There will be a new drug for hypertension. Two substances in one tablet.
- Polpharma will receive nearly PLN 10 million in funding from the European Funds for Modern Economy for the development of a two-component drug for use in hypertension
- Until now, both active substances are used in the form of single, separate tablets.
- - This is not only a milestone in the treatment of hypertension - it is also a significant impulse for the development of innovation in the Polish economy - comments Sebastian Szymanek, President of the Management Board of Polpharma SA
- - I hope that Polpharma's example will inspire other change leaders to conduct research and development work with support from European Funds - emphasizes Prof. Jerzy Małachowski, PhD, DSc, Eng.
The National Centre for Research and Development and Polpharma SA Pharmaceutical Works have signed an agreement to co-finance a project focused on the treatment of hypertension. The project received nearly PLN 10 million in funding from the European Funds for Modern Economy program.
The aim of the Polpharma SA project is to develop a complex oral preparation with hypotensive properties, i.e. lowering blood pressure in a combination of two active substances (API).
Until now, both active substances have been used in single, separate tablets, so combining them into one represents an innovation in hypertension therapy. Research and development will explore various dose combinations of both active substances to find the most effective and best-tolerated solutions.
The project will be implemented until the end of 2029.
"This is not only a milestone in hypertension treatment – it is also a significant boost for the development of innovation in the Polish economy. Thanks to such actions, we are strengthening Poland's position on the global pharmaceutical map and building drug safety both in the country and across Europe," commented Sebastian Szymanek, CEO of Polpharma SA.
It is estimated that approximately 40% of the global population between the ages of 35 and 64, and over 75% of those over 65, suffer from hypertension. According to the World Health Organization, an average of one in four men and one in five women suffer from hypertension. This means that hypertension affects over 1.3 billion people worldwide. However, one in three patients discontinues treatment after just six months. Combination therapy is a more patient-friendly form of pharmacotherapy.
In 2026, the National Centre for Research and Development plans to launch two more "SMART Path – Projects Implemented in Consortia" calls for proposals under the European Funds for Modern Economy program. The first SMART Path call for proposals for consortia, with an allocation of PLN 700 million, will be announced in February 2026. NCBR plans to announce the next call in the second half of next year.
In April 2026, the National Centre for Research and Development will launch additional calls for proposals under the Strategic Technology Platform for Europe, including a thematic focus on biotechnology. This will be another opportunity to submit breakthrough technologies critical to Europe, which will reduce its dependence on external markets.
"I hope that Polpharma's example will inspire other change leaders to conduct research and development with support from European Funds. The money is on the table, but we will only allocate it to the most promising projects," emphasized Prof. Jerzy Małachowski, PhD, DSc, Eng.
Copyrighted material - reprint rules are specified in the regulations .
rynekzdrowia
